The United States Medical Acquisition Activity (USAMRAA) recently announced intentions to award a sole-source contract to Southwest Research Institute (SwRI) to procure a variety of reactivators and aryl oximes to be used in on-going research testing for potential application in reactivation of organophosphate-inhibited acetylcholinesterase.
The intial development of these specific compounds was executed under a research grant (HDTRA-10-C-0041). SWRI holds the patents on these compounds and the synthesis techniques used to make them.
USAMRAA will issue a firm-fixed price requirements-type contract to SwRI with an estimated total value is $2,880,000.00 for a base plus three option years award.
The contracting action was announced under Solicitation Number: W81XWH13T0040.
